SCHEDULE 13G: Caligan Partners and David Johnson Disclose 5.2% Passive Stake in Y-mAbs Therapeutics
Beneficial Ownership Report
Investment firm Caligan Partners LP and its Managing Partner David Johnson have disclosed a passive 5.2% beneficial ownership stake in Y-mAbs Therapeutics, Inc., holding 2,342,609 shares of common stock.
Summary
- Caligan Partners LP, a Delaware limited partnership, and David Johnson, its Managing Partner, have filed a Schedule 13G, reporting beneficial ownership of Y-mAbs Therapeutics, Inc. common stock.
- The reporting persons collectively beneficially own 2,342,609 shares of Y-mAbs Therapeutics, Inc. common stock.
- This ownership represents 5.2% of the company's total outstanding common stock.
- The shares are held with shared voting power and shared dispositive power for the entire 2,342,609 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Y-mAbs Therapeutics, Inc.
- The percentage of class is calculated based on 45,218,177 shares of Common Stock outstanding as of February 25, 2025, as reported in the Company's Annual Report on Form 10-K filed on March 4, 2025.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Caligan Partners LP and David Johnson in Y-mAbs Therapeutics, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common for institutional investors crossing beneficial ownership thresholds and do not inherently signal a change in the company's strategic direction or industry standing, but rather an investment decision by the reporting entities.
Stakeholder Impact
- Shareholders: Disclosure of a significant passive stake by an institutional investor provides transparency regarding the ownership structure of Y-mAbs Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-02-25 | Date as of which 45,218,177 shares of Common Stock were reported outstanding in the Company's Annual Report on Form 10-K. |
| 2025-03-04 | Date Y-mAbs Therapeutics, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 2025-03-31 | Date of event which requires the filing of this statement (beneficial ownership threshold crossed). |
| 2025-05-14 | Date of filing of this Schedule 13G statement. |
Keywords
Y-mAbs Therapeutics, Caligan Partners, David Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.